-
1دورية أكاديمية
المؤلفون: Asche, Carl1 cva@uic.edu, Hippler, Stephen2, Eurich, Dean3
المصدر: PharmacoEconomics. Jan2014, Vol. 32 Issue 1, p15-27. 13p.
مصطلحات موضوعية: *COST effectiveness, PEOPLE with diabetes, GLUCAGON-like peptide-1 receptor, SYSTOLIC blood pressure, GLYCOSYLATED hemoglobin, SENSITIVITY analysis
-
2دورية أكاديمية
المؤلفون: Güven, Alper Tuna
المصدر: PharmacoEconomics; Aug2023, Vol. 41 Issue 8, p843-844, 2p
مصطلحات موضوعية: REIMBURSEMENT, DIABETES, DAPAGLIFLOZIN, GLUCAGON-like peptide-1 agonists, TYPE 2 diabetes, PHARMACEUTICAL policy, GLUCAGON-like peptide-1 receptor
-
3
المؤلفون: Minghuan Jiang, Lei Si, Dongzhe Hong, Wai-Kit Ming, Yan Li, Hui Shao, Yingnan Zhao, Lizheng Shi
المصدر: PharmacoEconomics. 37(6)
مصطلحات موضوعية: medicine.medical_specialty, Cost effectiveness, medicine.medical_treatment, Cost-Benefit Analysis, MEDLINE, Glucagon-Like Peptide-1 Receptor, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Diabetes mellitus, medicine, Humans, Hypoglycemic Agents, Insulin, 030212 general & internal medicine, Sodium-Glucose Transporter 2 Inhibitors, Dipeptidyl peptidase-4, Glucagon-like peptide 1 receptor, Pharmacology, Dipeptidyl-Peptidase IV Inhibitors, business.industry, 030503 health policy & services, Health Policy, Public Health, Environmental and Occupational Health, Guideline, medicine.disease, Glucagon-like peptide-1, 0305 other medical science, business
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6221c2146f9ad8736bb6877f53a5df6Test
https://pubmed.ncbi.nlm.nih.gov/31485924Test -
4
المؤلفون: Stephen Hippler, Carl V. Asche, Dean T. Eurich
المصدر: PharmacoEconomics. 32(1)
مصطلحات موضوعية: endocrine system, medicine.medical_specialty, endocrine system diseases, Cost-Benefit Analysis, Dipeptidyl Peptidase 4, Glucagon-Like Peptide-1 Receptor, Decision Support Techniques, Diabetes mellitus, medicine, Receptors, Glucagon, Humans, Hypoglycemic Agents, Intensive care medicine, Dipeptidyl peptidase-4, Randomized Controlled Trials as Topic, Pharmacology, Dipeptidyl-Peptidase IV Inhibitors, Insulin glargine, Liraglutide, business.industry, Health Policy, digestive, oral, and skin physiology, Public Health, Environmental and Occupational Health, nutritional and metabolic diseases, Type 2 Diabetes Mellitus, medicine.disease, Metformin, Models, Economic, Treatment Outcome, Diabetes Mellitus, Type 2, Quality-Adjusted Life Years, Rosiglitazone, business, Exenatide, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bf96f34fd84afa07b19c8f036c0c983Test
https://pubmed.ncbi.nlm.nih.gov/24357160Test